Literature DB >> 7763085

Expression of the p53 protein in malignant melanomas as a prognostic indicator.

M Yamamoto1, H Takahashi, K Saitoh, T Horikoshi, M Takahashi.   

Abstract

It is currently widely accepted that the tumour suppressor gene p53 is critically involved in the proliferation and differentiation of tumour cells including melanoma cells. In the present study, we examined 60 cases of primary melanoma to compare the expression of p53 protein with conventional prognostic markers for melanoma such as clinical and histological parameters. No correlation was found between the p53 protein and clinical factors except for the presence of a metastatic node and development to clinical stage II. However, the expression of p53 protein was significantly associated with tumour thickness over 1.5 mm, levels IV and V of invasion, the presence of ulceration, and high mitotic rate for 5-year survival rate. Although many questions still remain to be answered, our results and those of others for various other malignant tumours, implicate p53 in malignant transformation of pigment cells. Indeed, it could be a new marker for an unfavourable prognosis of malignant melanoma, even though the gene mutation in this highly lethal tumour has yet to be established.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7763085     DOI: 10.1007/BF01262323

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  30 in total

1.  Expression of p53 protein in cutaneous melanoma.

Authors:  L A Akslen; O Mørkve
Journal:  Int J Cancer       Date:  1992-08-19       Impact factor: 7.396

2.  Cancer genes. Telling changes of base.

Authors:  A L Harris
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

3.  Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.

Authors:  A Breslow
Journal:  Ann Surg       Date:  1970-11       Impact factor: 12.969

4.  Evaluation of melanin-related metabolites as markers of melanoma progression.

Authors:  T Horikoshi; S Ito; K Wakamatsu; H Onodera; H Eguchi
Journal:  Cancer       Date:  1994-02-01       Impact factor: 6.860

5.  Overexpression of p53 is a late event in the development of malignant melanoma.

Authors:  N J Lassam; L From; H J Kahn
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

6.  Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.

Authors:  J Bártek; J Bártková; B Vojtĕsek; Z Stasková; J Lukás; A Rejthar; J Kovarík; C A Midgley; J V Gannon; D P Lane
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

7.  Expression of mutant p53 in melanoma.

Authors:  J R Stretch; K C Gatter; E Ralfkiaer; D P Lane; A L Harris
Journal:  Cancer Res       Date:  1991-11-01       Impact factor: 12.701

8.  p53 Mutation and MDM2 amplification in human soft tissue sarcomas.

Authors:  F S Leach; T Tokino; P Meltzer; M Burrell; J D Oliner; S Smith; D E Hill; D Sidransky; K W Kinzler; B Vogelstein
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

9.  Tumour thickness and the site and time of first recurrence in cutaneous malignant melanoma (stage I).

Authors:  G W Milton; H M Shaw; G A Farago; W H McCarthy
Journal:  Br J Surg       Date:  1980-08       Impact factor: 6.939

10.  Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.

Authors:  A S Sarkis; G Dalbagni; C Cordon-Cardo; Z F Zhang; J Sheinfeld; W R Fair; H W Herr; V E Reuter
Journal:  J Natl Cancer Inst       Date:  1993-01-06       Impact factor: 13.506

View more
  4 in total

1.  Correlation of cell cycle regulatory proteins (p53 and p16(ink)⁴(a)) and bcl-2 oncoprotein with mitotic index and thickness of primary cutaneous malignant melanoma.

Authors:  Miloš Kostov; Zaklina Mijović; Dragan Mihailović; Snežana Cerović; Miroslav Stojanović; Marija Jelić
Journal:  Bosn J Basic Med Sci       Date:  2010-11       Impact factor: 3.363

Review 2.  Transcription factors and other dysregulated proteins in melanoma prognosis.

Authors:  J M Karjalainen
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

3.  p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival.

Authors:  J M Karjalainen; M J Eskelinen; J K Kellokoski; M Reinikainen; E M Alhava; V M Kosma
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

4.  p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis.

Authors:  Rubeta N Matin; Anissa Chikh; Stephanie Law Pak Chong; David Mesher; Manuela Graf; Paolo Sanza'; Valentina Senatore; Maria Scatolini; Francesca Moretti; Irene M Leigh; Charlotte M Proby; Antonio Costanzo; Giovanna Chiorino; Rino Cerio; Catherine A Harwood; Daniele Bergamaschi
Journal:  J Exp Med       Date:  2013-02-18       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.